These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32905551)

  • 1. The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience.
    Adrish M; Chilimuri S; Sun H; Mantri N; Yugay A; Zahid M
    Cureus; 2020 Sep; 12(9):e10217. PubMed ID: 32905551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.
    Rosen AB; Karter AJ; Liu JY; Selby JV; Schneider EC
    J Gen Intern Med; 2004 Jun; 19(6):669-75. PubMed ID: 15209606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.
    Rubin SJS; Falkson SR; Degner NR; Blish CA
    J Clin Transl Sci; 2021; 5(1):e8. PubMed ID: 34611496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
    Steely AM; Callas PW; Bertges DJ;
    J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery.
    Hollmann C; Fernandes NL; Biccard BM
    Anesth Analg; 2018 Sep; 127(3):678-687. PubMed ID: 29381513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure.
    Adachi S; Miura SI; Shiga Y; Arimura T; Morii J; Kuwano T; Kitajima K; Iwata A; Morito N; Fujimi K; Yahiro E; Nishikawa H; Saku K
    Int Heart J; 2017 May; 58(3):385-392. PubMed ID: 28484118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.
    Orlić L; Mikolasević I; Sladoje-Martinović B; Bubić I; Pavletić-Persić M; Racki S
    Coll Antropol; 2013 Sep; 37(3):809-14. PubMed ID: 24308221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R; Tonolo G
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R; Sellers F
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.
    Rim MY; Ro H; Kang WC; Kim AJ; Park H; Chang JH; Lee HH; Chung W; Jung JY
    Am J Kidney Dis; 2012 Oct; 60(4):576-82. PubMed ID: 22658321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
    Gadzhanova S; Roughead EE; Bartlett LE
    Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receipt of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers among Medicare Beneficiaries with Diabetes and Hypertension.
    Wang J; Surbhi S; Kuhle JW
    J Pharm Health Serv Res; 2014 Mar; 5(1):67-74. PubMed ID: 24563667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.